Oseltamivir as a cause of acute enterorrhagia

Beraldi-Magalhães, Francisco; Batista, Vera; Cordeiro-Santos, Marcelo

doi:10.1016/j.bjid.2016.07.010

Cited by 5 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1 ] Oseltamivir is a neuraminidase inhibitor that was licensed by the US Food and Drug Administration (FDA) in 1999 to treat influenza. In the nearly 2 decades, the most commonly reported adverse effects of oseltamivir were nausea and vomiting, [ 2 , 3 ] whereas the severe or rare adverse effects include psychiatric manifestations, [ 4 – 8 ] tongue swelling, [ 9 ] enterorrhagia, [ 10 – 13 ] dyskinesia, [ 14 ] bradycardia, [ 15 ] glaucoma, transient myopia, [ 16 ] and Stevens–Johnson syndrome. [ 17 ] However, alimentary tract hemorrhage and liver injury after oseltamivir treatment have been rarely reported.…”

Section: Introductionmentioning

confidence: 99%

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir

Fang

Zhou

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Oseltamivir-induced alimentary tract hemorrhage and liver injury are rarely reported in children and adult individuals. In this study, we described the clinical features and outcomes of oseltamivir-induced alimentary tract hemorrhage and liver injury in a child.Patient concerns:Here, we present a case of a 6-year-old Asian boy with hematemesis and elevated alanine aminotransferase (ALT) (80 U/L) and aspartate aminotransferase (AST) (69 U/L) levels on day 2 of oseltamivir administration. The presence of alimentary tract hemorrhage and liver injury was diagnosed. The ALT level reached 1931.3 U/L, accompanied by an increase in total bilirubin (TBIL) to 53.3 μmol/L on day 15 after oseltamivir administration. Additional tests were performed to determine the presence of viruses that can cause hepatitis and autoantibodies, and the results from these tests were all negative.Diagnosis:Drug-induced liver injury was considered.Interventions:This patient was treated with compound glycyrrhizin and reduced glutathione and glucocorticoid.Outcomes:The liver enzymes recovered within 6 weeks without any symptoms of liver-related diseases after treatment with glucocorticoid. This treatment therefore helps reduce ALT and TBIL levels and protects the liver from further injury.Lessons:Oral oseltamivir is widely used to treat influenza and the adverse effects of this drug were mostly mild. However, clinicians should always be alert for oseltamivir-induced alimentary tract hemorrhage and liver injury when prescribing oseltamivir for children.

show abstract

Section: Introductionmentioning

confidence: 99%

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir

Fang

Zhou

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

Antiviral influenza treatments and hemorrhage‐related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database

Sarker,

Carkovic,

Ptaszek

et al. 2024

Pharmacotherapy

View full text Add to dashboard Cite

Study ObjectiveTo determine whether there is a signal for gastrointestinal (GI) or intracranial (IC) hemorrhage associated with the use of antiviral medications for influenza in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.DesignDisproportionality analysis.Data SourceThe FAERS database was searched using OpenVigil 2.1 to identify GI and IC hemorrhage events reported between 2004 and 2022.MeasurementsAntiviral medications for influenza included the following: oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Hemorrhage events were identified using Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries for GI and IC hemorrhages. Reporting odds ratios (RORs) were calculated to compare the occurrence of GI and IC hemorrhage events between antiviral drugs for influenza and (i) all other medications and (ii) antibiotics. RORs were also calculated for each of the individual antiviral medications.Main ResultsA total of 245 cases of GI hemorrhage and 23 cases of IC hemorrhage were identified in association with four antivirals. In comparison with all other drugs, the RORs of GI hemorrhage for oseltamivir, zanamivir, peramivir, baloxavir, and all antivirals combined were 1.17, 0.62, 4.44, 2.53, and 1.22, respectively, indicating potential variations in GI hemorrhage risk among the antivirals. In contrast, in comparison with all other drugs, the RORs of IC hemorrhage for oseltamivir (0.44), zanamivir (0.16), baloxavir (0.44), and all antivirals combined (0.41) were less than 1.0 which is consistent with no elevated risk of IC hemorrhage.ConclusionIn this study, some signals for GI hemorrhage were observed, particularly for peramivir and baloxavir marboxil. Further investigation is warranted to better understand and evaluate the potential risks of GI hemorrhage associated with antiviral treatments for influenza.

show abstract

Oseltamivir

2016

Reactions Weekly

View full text Add to dashboard Cite

Oseltamivir as a cause of acute enterorrhagia

Cited by 5 publications

References 3 publications

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir

Antiviral influenza treatments and hemorrhage‐related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database

Oseltamivir

Contact Info

Product

Resources

About